Drug name - Cotellic

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7803839 GENENTECH INC Azetidines as MEK inhibitors for the treatment of proliferative diseases
Nov, 2029

(7 years from now)

US10478400 GENENTECH INC Immediate-release tablets containing combimetinib and methods of making and using the same
Jun, 2036

(13 years from now)

US10590102 GENENTECH INC Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]methanone
Jun, 2036

(13 years from now)

CN109053523A GENENTECH INC As Mek Inhibitors For The Treatment Of Proliferative Diseases Of Azetidine
Oct, 2026

(4 years from now)

CN109053523B GENENTECH INC Azdines As Mek Inhibitors For The Treatment Of Proliferative Diseases
Oct, 2026

(4 years from now)

CN104892582B GENENTECH INC As Arylmethylazetidine For Mek Inhibitor For Treating Proliferative Diseases
Oct, 2026

(4 years from now)

CN104892582A GENENTECH INC As Azetidine Mek Inhibitors For The Treatment Of Proliferative Diseases
Oct, 2026

(4 years from now)

CN101365676B GENENTECH INC Azetidines As Mek Inhibitors For The Treatment Of Proliferative Diseases
Oct, 2026

(4 years from now)

CN101365676A GENENTECH INC Azetidines As Mek Inhibitors For The Treatment Of Proliferative Diseases
Oct, 2026

(4 years from now)

CN103524392A GENENTECH INC Azetidines As Mek Inhibitors For The Treatment Of Proliferative Diseases
Oct, 2026

(4 years from now)

CN103524392B GENENTECH INC As Mek Inhibitors For The Treatment Of Proliferative Diseases Of Azetidine
Oct, 2026

(4 years from now)

CN108135854B GENENTECH INC Immediate Release Tablet Containing Medicine And Method For Forming Tablet
Jun, 2036

(13 years from now)

CN108135854A GENENTECH INC Drug-Containing Immediate Release Tablets And A Method Of Forming A Tablet
Jun, 2036

(13 years from now)

IN200802771P1 GENENTECH INC Mek Inhibitors And Methods Of Thier Use
Oct, 2026

(4 years from now)

IN313177B GENENTECH INC Mek Inhibitors And Methods Of Thier Use
Oct, 2026

(4 years from now)

EP1934174B1 GENENTECH INC Azetidines As Mek Inhibitors For The Treatment Of Proliferative Diseases
Oct, 2026

(4 years from now)

EP1934174A1 GENENTECH INC Azetidines As Mek Inhibitors For The Treatment Of Proliferative Diseases
Oct, 2026

(4 years from now)

EP3316867B1 GENENTECH INC Immediate-Release Tablets Containing A Drug And Processes For Forming The Tablets
Jun, 2036

(13 years from now)

EP3316867A1 GENENTECH INC Immediate-Release Tablets Containing A Drug And Processes For Forming The Tablets
Jun, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8362002 GENENTECH INC Azetidines as MEK inhibitors for the treatment of proliferative diseases Oct, 2026

(4 years from now)

US11087354 GENENTECH INC Combination therapies Jun, 2034

(11 years from now)

Drugs and Companies using COBIMETINIB FUMARATE ingredient

Treatment: Method of using cobimetinib for the treatment of melanoma

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.